SecBot SecBot
PRESS-RELEASE ·Filed Aug 19, 2026

TLX

Telix Pharmaceuticals Limited
BULLISH
Impact 7/10
Horizonimmediate Processed2mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▲ Bullish

The strong H1 beat and maintained guidance at the upper end are clear positives, but the ATM facility creates potential dilution. Traders should watch for the prospectus supplement filing to gauge the pace and size of any ATM sales, which could cap near-term upside. The PDUFA date for Pixclara on September 11, 2026, is a key catalyst.

DirectionBullish
Confidencehigh
Horizonimmediate

Drugs in focus

TLX drug pipeline →

TLX591-Tx

● Neutral Named in this press release
Impact
Phase
Phase 3
Time to market
Likely 2028+ (Phase 3 Part 2 enrollment underway, followed by event-driven rPFS readout, then regulatory filing)
Next catalyst
None dated

What to watchWatch for enrollment completion updates on ProstACT Global Part 2 and any interim rPFS data. The stock is heavily influenced by Illuccix/Gozellix revenue execution, so TLX591-Tx is a pipeline upside option, not the core thesis today. Near-term catalysts center on Telix's imaging franchise (Pixclara PDUFA) rather than this therapeutic.

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$12.42
T+0 close · Aug 19, 2026 · via day close
Latest settled
−24.64%
T+60 · $9.36
Vs SPY
−23.80%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 20 $12.42entry
  2. T+1 · 3mo ago −8.78%α −9.19% · $11.33
  3. T+5 · 3mo ago −8.41%α −9.53% · $11.38
  4. T+20 · 2mo ago +0.68%α +0.68% · $12.51
  5. T+60 · 4d ago −24.64%α −23.80% · $9.36

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Telix Pharmaceuticals reported H1 2026 revenue of $477M, up 22% YoY, and a net profit of $38M vs a loss of $2M in H1 2025, driven by strong commercial performance and a $40M non-refundable payment from Regeneron. The company reaffirmed FY 2026 revenue guidance at the upper end of $950M-$970M and expects total revenue and other income to exceed $1B, while also establishing an ATM facility for potential equity issuance. The strong beat on profitability and maintained guidance are positive, but the ATM facility introduces dilution overhang, tempering the overall bullish signal.

Key Financial Metrics

Revenue
$477.0M
est $311.6M · +53.1% · +22.3% YoY
Guidance
$950M-$970M
maintained
Gross Margin
55%

Key Facts

  • H1 2026 revenue of $477M, up 22% YoY from $390M
  • Net profit of $38M vs loss of $2M in H1 2025
  • Adjusted EBITDA of $52M, up 146% YoY from $21M
  • Precision Medicine segment revenue up 27% YoY with gross margin of 65%
  • FY 2026 revenue guidance reaffirmed at upper end of $950M-$970M, total revenue and other income expected to exceed $1B
  • Established an ATM facility to sell up to undisclosed amount of ADSs at market prices
  • Cash balance of $252M as of June 30, 2026
  • Entered strategic collaboration with Regeneron, receiving $40M initial payment

Financial Impact

Revenue of $477M vs consensus $311.6M (beat by ~53%), net profit of $38M vs consensus EPS of -$0.01 (strong beat). FY guidance of $950M-$970M revenue implies H2 revenue of $473M-$493M.

revenueepsebitdacash

Risk Factors

  • ATM facility could lead to dilution if shares are sold at current market prices
  • R&D spending of $124M in H1 (vs $82M in H1 2025) may pressure near-term profitability if revenue growth slows
  • BLA resubmission for Zircaix (TLX250-Px) remains pending with FDA

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3348062

Track record

27 reports on TLX

Performance horizon

10 of 20 bullish or bearish reports moved the stock their way by T+1. Best: +29.26% at T+20 after the Jun 1, 2026 report. 18 of 20 went positive at some point.

Filters
  1. Oct 29, 202618d ago 6-K Neutral 5/10 Entry $9.10 to $9.05 Now $8.92 −1.98% ▼ −0.55% −0.07% vs SPY
  2. Oct 20, 202627d ago 6-K Neutral 4/10 No price data
  3. Oct 20, 202627d ago Press Release Bullish 6/10 Entry $10.03 to $9.54 Now $8.92 −11.07% ▼ −4.89% −3.70% vs SPY
  4. Sep 29, 20266w ago 6-K Bullish 6/10 Entry $10.97 to $10.72 Now $8.92 −18.69% ▼ −2.28% −2.46% vs SPY
  5. Sep 21, 20268w ago 6-K Bullish 7/10 Entry $11.31 to $11.95 Now $8.92 −21.13% ▲ +5.66% +5.67% vs SPY
  6. Sep 20, 20268w ago Press Release Bullish 7/10 Entry $11.31 to $11.95 Now $8.92 −21.13% ▲ +5.66% +5.67% vs SPY
  7. Sep 14, 20269w ago 6-K Bullish 8/10 Entry $12.83 to $11.83 Now $8.92 −30.48% ▼ −7.79% −7.35% vs SPY
  8. Sep 14, 20269w ago Press Release Bullish 8/10 Entry $11.78 to $12.83 Now $8.92 −24.28% ▲ +8.91% +9.37% vs SPY
  9. Sep 1, 202610w ago 6-K Bullish 7/10 Entry $11.45 to $11.74 Now $8.92 −22.10% ▲ +2.53% +1.49% vs SPY
  10. Sep 1, 202610w ago Press Release Bullish 6/10 Entry $11.45 to $11.74 Now $8.92 −22.10% ▲ +2.53% +1.49% vs SPY
Showing 10 of 27

US Market Status

Market Closed · Opens Wed (10h 17m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 19, 2026